HomeAI · summaries
Storia in 3 fonti
ASCO 2026: Talzenna and Xtandi combo has first-line promise in HRR altered-mCSPC - Pharmaceutical Technology
At ASCO 2026, Pfizer presented top line data for the Phase III TALAPRO-3 clinical trial, evaluating Talzenna combined with Xtandi.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
medpagetoday.com
Treatment Intensification Slows Metastatic Hormone-Sensitive Prostate Cancer
Talazoparib plus enzalutamide reduces progression risk by 50% in men with DNA repair alterations
- ·
biopharmadive.com
ASCO ‘26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer
At the year’s biggest cancer meeting, a high-stakes clash between two popular drug classes erupted, and scientists made headway against a once-insurmountable foe.
- ·
pharmaceutical-technology.com
ASCO 2026: Talzenna and Xtandi combo has first-line promise in HRR altered-mCSPC - Pharmaceutical Technology
At ASCO 2026, Pfizer presented top line data for the Phase III TALAPRO-3 clinical trial, evaluating Talzenna combined with Xtandi.